EVT.F - Evotec AG

Frankfurt - Frankfurt Delayed Price. Currency in EUR
17.08
+0.91 (+5.60%)
At close: 7:52PM CEST
Stock chart is not supported by your current browser
Previous Close16.17
Open16.40
Bid17.08 x 400000
Ask17.19 x 400000
Day's Range15.95 - 17.17
52 Week Range11.52 - 23.35
Volume32,583
Avg. Volume33,893
Market Cap2.517B
Beta (3Y Monthly)0.40
PE Ratio (TTM)81.72
EPS (TTM)0.21
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.58
  • ACCESSWIRE6 days ago

    Evotec and Celgene Expand iPSC Collaboration to Include Additional Cell Lines

    $ 6 M PAYMENT TO ACCESS ADDITIONAL CELL LINES HAMBURG, GERMANY / ACCESSWIRE / October 11, 2018 / Evotec AG (FSE: EVT) (XETRA: EVT) (OTC PINK: EVTCY), (TecDAX, ISIN: DE0005664809) announced today that the ...

  • ACCESSWIRE13 days ago

    Evotec Signs Agreement With Sanofi To Advance Early Stage Academic Research Into Novel Therapeutic Candidates

    THE CREATION OF LAB031 IS DESIGNED TO TRANSLATE ACADEMIC RESEARCH INTO DRUG DISCOVERY CANDIDATES EVOTEC AIMS TO GENERATE MULTIPLE LEAD CANDIDATES FOR SANOFI OVER THREE YEARS ACROSS MULTIPLE THERAPEUTIC ...

  • ACCESSWIRElast month

    Evotec And Almirall Enter Into Research Collaboration In The Field Of Dermatological Diseases

    - COLLABORATION IS FOCUSED ON FIRST-IN-CLASS THERAPIES TO TREAT DERMATOLOGICAL DISEASES - COLLABORATION LEVERAGES A NOVEL APPROACH TO DISRUPT CELL SIGNALLING, VALIDATED BY EVT INNOVATE HAMBURG, GERMANY ...

  • What does Evotec AG’s (ETR:EVT) Balance Sheet Tell Us About Its Future?
    Simply Wall St.last month

    What does Evotec AG’s (ETR:EVT) Balance Sheet Tell Us About Its Future?

    Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Evotec AG (ETR:EVT), with a market cap of €3.29b, are often out of the spotlight.Read More...

  • ACCESSWIRElast month

    Evotec AG Listed In MDAX

    DUAL-LISTING OF EVOTEC AG SHARE IN TECDAX AND MDAX AS OF 24 SEPTEMBER 2018 HAMBURG, GERMANY / ACCESSWIRE / September 6, 2018 / Evotec AG (FSE: EVT) (XETRA: EVT) (OTC PINK: EVTCY), (TecDAX, ISIN: DE0005664809) ...

  • ACCESSWIRElast month

    Evotec And Celgene Enter Partnership In The Field Of Targeted Protein Degradation

    THE COLLABORATION WILL FOCUS ON TARGETED PROTEIN DEGRADATION EVOTEC'S PANOMICS AND DATA ANALYTICS PLATFORMS WILL BE LEVERAGED FINANCIALS INCLUDE UPFRONT PAYMENT AS WELL AS SIGNIFICANT POTENTIAL MILESTONE-BASED ...

  • ACCESSWIRE2 months ago

    Evotec And CHDI Foundation Extend Ongoing Collaboration To Fight Huntington's Disease

    HAMBURG, GERMANY / ACCESSWIRE / August 30, 2018 / Evotec AG (EVT.DE) (EVT.DE) (OTC PINK: EVTCY), (TecDAX, ISIN: DE0005664809) today announced that CHDI Foundation, Inc. ("CHDI") has extended its collaboration with Evotec through to 2023. Over this period, CHDI may fund up to 75 full-time scientists at Evotec.

  • ACCESSWIRE2 months ago

    Evotec And Centogene Sign Global Strategic Partnership On Drug Discovery Projects In Rare Genetic Diseases

    - JOINT DRUG DISCOVERY PROJECTS COMBINE CENTOGENE'S PATIENT ACCESS AND BIOMARKER EXPERTISE WITH EVOTEC'S LEADING IPSC PLATFORM HAMBURG, ROSTOCK, GERMANY / ACCESSWIRE / August 27, 2018 / Evotec AG (FSE: ...

  • ACCESSWIRE2 months ago

    Evotec Partner Haplogen Enters Into Collaboration With Bayer

    HAMBURG, GERMANY / ACCESSWIRE / August 14, 2018 / Evotec AG (EVT.F) (EVT.DE) (OTC PINK:EVTCY), (TecDAX, ISIN: DE0005664809) announced today that Haplogen GmbH ("Haplogen"), a Vienna-based biotechnology company and collaboration partner of Evotec, has entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease ("COPD"). Since Haplogen and Evotec began collaborating in 2012, collectively, they built a robust portfolio of pulmonary therapeutic programmes based on the industry-leading drug discovery platforms and know-how of both companies.

  • ACCESSWIRE2 months ago

    Evotec AG Reports First Half-Year 2018 Results And Corporate Updates

    - SIGNIFICANT GROWTH OF EVT EXECUTE AND EVT INNOVATE - 67% INCREASE IN GROUP REVENUES, 47% INCREASE IN ADJUSTED GROUP EBITDA - REPAYMENT OF 50% (EUR 70 M) OF APTUIT ACQUSITION LOAN WITHIN ONE YEAR - WEBCAST ...

  • With An ROE Of 6.00%, Can Evotec AG (ETR:EVT) Catch Up To The Industry?
    Simply Wall St.2 months ago

    With An ROE Of 6.00%, Can Evotec AG (ETR:EVT) Catch Up To The Industry?

    I am writing today to help inform people who are new to the stock market and want to learn about Return on Equity using a real-life example. Evotec AG’s (ETR:EVT)Read More...

  • ACCESSWIRE3 months ago

    Evotec Repays 50% Of EUR 140 M Acquisition Loan

    STRONG OPERATIONAL CASHFLOW FACILITATES REPAYMENT OF EUR 70 M WITHIN THE FIRST YEAR OF THE LOAN TERM EUR 140 M LOAN WAS TAKEN TO EXPAND EVOTEC'S VALUE CHAIN WITH APTUIT IN AUGUST 2017 HAMBURG, GERMANY ...

  • ACCESSWIRE3 months ago

    Evotec Receives Milestone Payment For Start Of Phase II Trial In Its Multi-Target Alliance With Bayer

    HAMBURG, GERMANY / ACCESSWIRE / July 19, 2018 / Evotec AG (EVT.DE), (EVT.DE) (ISIN:DE0005664809) announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting in a payment of EUR 4 m to Evotec. Chronic cough is a major global health burden and has a significant impact on the quality of life of millions of people. Currently, no therapies are approved for the treatment of chronic cough.

  • Updates on the Sanofi-Evotec Diabetes Business Collaboration
    Market Realist3 months ago

    Updates on the Sanofi-Evotec Diabetes Business Collaboration

    On June 25, Sanofi and Evotec reached the second milestone of the diabetes business alliance they entered into in August 2015, with a payment of 3 million euros from Sanofi to Evotec after the latter had met “pre-agreed critical success criteria for a potential manufacturing process” for generating human induced pluripotent stem cell-derived beta cells. The deal aims to extend Evotec’s metabolic disease and stem cell-based drug discovery programs and enhance Sanofi’s extensive diabetes research and development pipeline. According to the agreement, Evotec is eligible to receive as much as 300 million euros in milestone-based payments from Sanofi as well as royalties and research payments. To date, the company has received 9 million euros in upfront milestone-based payments and research funding from Sanofi.

  • Sanofi Signs Over Anti-Infectives Unit to Evotec
    Market Realist3 months ago

    Sanofi Signs Over Anti-Infectives Unit to Evotec

    On June 15, Sanofi (SNY) and Evotec, a Germany-based drug discovery and development company, signed an agreement to transfer Sanofi’s anti-infectives unit to Evotec for $70 million. Sanofi will also transfer 100 employees to Evotec and licenses for more than ten infectious disease R&D (research and development) pipeline assets.

  • ACCESSWIRE3 months ago

    Evotec Confirm Closing Of Transaction With Sanofi To Accelerate Infectious Disease Research And Development

    HAMBURG, GERMANY / ACCESSWIRE / July 3, 2018 / Evotec AG (EVT.DE), (EVT.DE) (ISIN:DE0005664809) today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi's infectious disease unit including licensing-in the majority of Sanofi's infectious disease research portfolio, has been successfully closed with effect from 01 July 2018. The transaction will result in a EUR 60 m upfront cash payment and a guaranteed financial commitment from Sanofi to Evotec for five years. Evotec will accelerate the infectious disease research pipeline development and initiate new open innovation R&D initiatives in anti-infectives.

  • ACCESSWIRE4 months ago

    Evotec Achieves Second Milestone in Diabetes Alliance With Sanofi

    COMPANIES ARE AT THE FOREFRONT OF BETA CELL REPLACEMENT THERAPEUTIC RESEARCH FOR DIABETES EVOTEC RECEIVES EUR 3 MILLION PAYMENT FROM SANOFI MILESTONE FURTHER DEMONSTRATES ADVANCEMENT OF EVT INNOVATE INITIATIVE ...

  • Is It The Right Time To Buy Evotec AG (ETR:EVT)?
    Simply Wall St.4 months ago

    Is It The Right Time To Buy Evotec AG (ETR:EVT)?

    Evotec AG (ETR:EVT), a life sciences company based in Germany, received a lot of attention from a substantial price increase on the XTRA over the last few months. As aRead More...

  • ACCESSWIRE4 months ago

    Resolutions of the Annual General Meeting 2018 of Evotec AG

    HAMBURG, GERMANY / ACCESSWIRE / June 20, 2018 / Evotec AG (FSE: EVT, XETRA: EVT) (ISIN:DE0005664809) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting 2018 with the required majorities. The strategy and its execution by the members of the Management Board and the Supervisory Board for the fiscal year 2017 were supported and approved.

  • ACCESSWIRE4 months ago

    Evotec And Sanofi Sign Definitive Agreement To Combat Infectious Diseases

    HAMBURG, GERMANY / ACCESSWIRE / June 18, 2018 / Evotec AG (EVT.F) (EVT.DE) (ISIN:DE0005664809) today announced having signed a transaction agreement with Sanofi to integrate Sanofi's infectious disease unit into its organisation.

  • Business Wire5 months ago

    Evotec Forms Academic Bridge 'LAB591' with Arix Bioscience and Fred Hutchinson Cancer Research Center

    Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today the formation of the LAB591 academic BRIDGE with Arix Bioscience plc ("Arix", London Stock Exchange: ARIX ) the Fred Hutchinson Cancer Research Center ("Fred Hutch"). LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development.

  • PR Newswire5 months ago

    Arix Bioscience Forms Strategic Collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to Foster New Companies in Cancer and Infectious Diseases

    Arix Bioscience plc ("Arix", London Stock Exchange: ARIX) a global healthcare and life science company supporting medical innovation, today announced the formation of the LAB591, an academic "BRIDGE" collaboration with the Fred Hutchinson Cancer Research Center ("Fred Hutch") and Evotec AG ("Evotec", Frankfurt Stock Exchange: EVT). LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development. Arix, Evotec and Fred Hutch plan to jointly select promising LAB591 research projects from the Fred Hutch labs.

  • Business Wire5 months ago

    Evotec and Celgene Expand IPSC Collaboration to Include Additional Cell Lines

    Evotec AG announced today that the Company will receive a $ 6 m payment from Celgene following Celgene's decision to expand the collaboration to include additional cell lines.

  • Benzinga5 months ago

    Celgene Forges Oncology Partnership With Germany's Evotec

    Celgene Corporation (NASDAQ: CELG ) — which is recently very much in the news, although for dubious reasons — has struck a partnership with Germany's Evotec AG (ADR) (OTC: EVTCY ), which partners with ...

  • Business Wire5 months ago

    Evotec and Celgene Enter into Strategic Oncology Partnership

    Evotec AG announced today that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.